Donnerstag, 27. Oktober 2016

  • Pressemitteilung BoxID 544940

Ypsomed doubles dividends to shareholders

(lifePR) (Burgdorf, ) The shareholders of Ypsomed Holding AG approved all proposals by the board of directors by a large majority at the regular general meeting held on 1st July 2015. For the 2014/15 fiscal year, a dividend of CHF 0.60 per share, exempt from withholding tax, will be paid to shareholders from capital reserves.

The shareholders approved all amendments to the statutes that were mainly required by the Ordinance Against Excessive Compensation in Swiss Listed Companies. The directors, Dr. h.c. Willy Michel, Anton Kräuliger, Prof. em. Norbert Thom and Gerhart Isler, have been reelected to their offices for one year until the next regular annual general meeting. Dr. h.c. Willy Michel was approved as president of the board of directors for the same period. For the first time, the shareholders also decided on the remuneration for the board of directors and management. They approved the respective proposals of the board of directors.

Über Ypsomed AG

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, autoimmune diseases, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.

Diese Pressemitteilungen könnten Sie auch interessieren

7x7 stellt nachhaltige Investments vor

, Finanzen & Versicherungen, 7×7 Unternehmensgruppe c/o 7x7sachwerte GmbH & Co. KG

Die Bonner 7x7finanz GmbH präsentiert sich am 12. November 2016 in Freiburg auf der Messe Grünes Geld. Dort können sich interessierte Anleger...

Altbau vor Kauf eingehend besichtigen

, Finanzen & Versicherungen, Wüstenrot & Württembergische AG

Vor dem Kauf eines älteren Hauses sollte man sich eingehend über den Zustand und durchgeführte Sanierungsarbeiten informieren. Denn es ist üblich,...

Firmenjubiläum bei der BKK ProVita in Nürnberg

, Finanzen & Versicherungen, BKK ProVita

Am 21.10.2016 feierte Frau Doris Tobisch ihr 25-jähriges Firmenjubiläum bei der BKK ProVita in Nürnberg. Im Rahmen einer kleinen Feierstunde...